3-吡啶氧基乙酸盐酸盐 | 471894-98-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-吡啶氧基乙酸盐酸盐
• 英文名称: pyridin-3-yloxyacetic acid hydrochloride
• 英文别名: 2-(pyridin-3-yloxy)acetic acid hydrochloride；[3]pyridyloxy-acetic acid ; hydrochloride；[3]Pyridyloxy-essigsaeure; Hydrochlorid；(Pyridin-3-yloxy)-acetic acid hydrochloride；2-pyridin-3-yloxyacetic acid;hydrochloride
• CAS: 471894-98-1
• 化学式: C₇H₇NO₃*ClH
• 分子量: 189.598
• InChiKey: KZYKMYREWFIOFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-吡啶氧基乙酸盐酸盐 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成
  参考文献：
  名称：

  Strong positive cooperativity in binding to the A3T3 repeat by Hoechst 33258 derivatives attaching the quinoline units at the end of a branched linker

  摘要：

  Hoechst 33258 derivatives with additional interacting moieties attached at the ends of branched linkers were synthesized, and their DNA binding properties were investigated with regard to the A3T3 repeat by measuring fluorescence spectra. The binding property of the ligand was investigated by fluorescence titration, and the titration data were analyzed using the McGhee-von Hippel method. Ligand 6Q with the quinolin-6-yloxyacetyl group and Ligand IQ with isoquinolin-6-yloxyacetyl group at the ends of the branched linkers exhibit highly positive cooperativity for the DNA having 5 A3T3 sites with 3 base-insertions between them with sequence selectivity. The strategy developed in this study may be generally applicable for designing ligands for repetitive DNA sequences. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.056
• 作为产物：
  描述：

  3-羟基吡啶 在 盐酸 、 sodium hydride 作用下， 以 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.5h， 生成 3-吡啶氧基乙酸盐酸盐
  参考文献：
  名称：

  Strong positive cooperativity in binding to the A3T3 repeat by Hoechst 33258 derivatives attaching the quinoline units at the end of a branched linker

  摘要：

  Hoechst 33258 derivatives with additional interacting moieties attached at the ends of branched linkers were synthesized, and their DNA binding properties were investigated with regard to the A3T3 repeat by measuring fluorescence spectra. The binding property of the ligand was investigated by fluorescence titration, and the titration data were analyzed using the McGhee-von Hippel method. Ligand 6Q with the quinolin-6-yloxyacetyl group and Ligand IQ with isoquinolin-6-yloxyacetyl group at the ends of the branched linkers exhibit highly positive cooperativity for the DNA having 5 A3T3 sites with 3 base-insertions between them with sequence selectivity. The strategy developed in this study may be generally applicable for designing ligands for repetitive DNA sequences. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.056

文献信息

• HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170349576A1

  公开（公告）日：2017-12-07

  The invention discloses compounds of Formula I, wherein X 1 , X 2 , R 1 , and R 2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明涉及一种公式I的化合物，其中X1、X2、R1和R2如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同的药物组合，以及通过给予本发明的化合物治疗囊性纤维化的方法。
• Compounds and pharmaceutical compositions for inhibiting mrp1
  申请人：——

  公开号：US20040116460A1

  公开（公告）日：2004-06-17

  The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1. 1

  本发明涉及一种式（I）的化合物，其对抑制耐药肿瘤具有用处，其中该耐药性部分或全部由MRP1.1赋予。
• P2X4 receptor antagonist
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US09382236B2

  公开（公告）日：2016-07-05

  The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(═O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.

  本发明涉及一种二氮杂吡啶衍生物，其由下述通式（I）表示（在该式中，R1和R2表示氢原子等，或者R1和R2结合在一起形成萘环等，与它们结合的苯环一起，R3和R4表示氢原子等，R5表示氢原子等，R6和R7表示氢原子等，X表示C、CH或N，Y表示N、NH或C（=O），前提是当X为N时，Y不是N或NH，当X为C或CH时，Y不是C（=O），Z表示氧原子或硫原子，A表示苯环等，B表示NHC（=O）等，D表示原子键等，E表示原子键等，G表示苯环，可以被取代等，m表示0至5的整数），或其药学上可接受的盐，以及P2X4受体拮抗剂。
• [EN] NAMPT INHBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE NAMPT ET LEURS UTILISATIONS
  申请人：REMEDY PLAN INC

  公开号：WO2022241257A1

  公开（公告）日：2022-11-17

  Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinucleotide (NAD), NAMPT signaling, a NAMPT pathway, and/or cellular metabolism. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Further provided are methods of manufacturing compounds of Formula (V). The compounds of the disclosure are of Formula (I), (II), (III), and (IV):

  本发明涉及调节（例如抑制）烟酰胺磷酸核糖转移酶（NAMPT）、烟酰胺单核苷酸（NMN）的产生、烟酰胺腺嘌呤二核苷酸（NAD）的产生、NAMPT信号传导、NAMPT途径和/或细胞代谢的化合物、方法、组合物、用途和试剂盒。在某些实施例中，这些化合物用于治疗疾病或疾病障碍。这些化合物可以通过靶向癌症干细胞来治疗癌症。在某些实施例中，这种癌症是结肠癌、胃癌、胃肠间质瘤、卵巢癌、肺癌、乳腺癌、胰腺癌、前列腺癌、睾丸癌、淋巴瘤、肝癌、子宫内膜癌、白血病或多发性骨髓瘤。此外，还提供了制造化合物公式（V）的方法。本公开的化合物为公式（I）、（II）、（III）和（IV）的化合物。
• Heteroaryl substituted pyridines and methods of use
  申请人：AbbVie S.à.r.l.

  公开号：US10138227B2

  公开（公告）日：2018-11-27

  The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明公开了式 I 的化合物、 其中X1、X2、R1和R2如本文所定义。本发明涉及治疗囊性纤维化的化合物及其用途、生产方法、包含本发明化合物的药物组合物以及通过施用本发明化合物治疗囊性纤维化的方法。